Find Tazemetostat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1467052-75-0, Tazemetostat monohydrobromide, Epz-6438 monohydrobromide, E-7438 hydrobromide, Ez438, Tazemetostat (hydrobromide)
Molecular Formula
C34H45BrN4O4
Molecular Weight
653.6  g/mol
InChI Key
UQRICAQPWZSJNF-UHFFFAOYSA-N
FDA UNII
6P89T5M073

Tazemetostat
Tazemetostat Hydrobromide is the hydrobromide salt form of tazemetostat, an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.
1 2D Structure

Tazemetostat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide
2.1.2 InChI
InChI=1S/C34H44N4O4.BrH/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40;/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40);1H
2.1.3 InChI Key
UQRICAQPWZSJNF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5.Br
2.2 Other Identifiers
2.2.1 UNII
6P89T5M073
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:2)

2. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrochloride (1:1)

3. E 7438

4. E-7438 Hydrobromide

5. E7438

6. Epz-6438

7. Epz-6438 Dihydrobromide

8. Epz-6438 Monohydrobromide

9. Epz-6438 Monohydrochloride

10. Epz-6438 Trihydrochloride

11. Ez-438

12. Ez438

13. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide

14. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide

15. Tazemetostat

16. Tazemetostat Dihydrobromide

17. Tazemetostat Hydrochloride

18. Tazemetostat Monohydrobromide

19. Tazemetostat Monohydrochloride

20. Tazemetostat Trihydrochloride

21. Tazverik

2.3.2 Depositor-Supplied Synonyms

1. 1467052-75-0

2. Tazemetostat Monohydrobromide

3. Epz-6438 Monohydrobromide

4. E-7438 Hydrobromide

5. Ez438

6. Tazemetostat (hydrobromide)

7. Epz-6438 Hydrobromide

8. Tazemetostat Hydrobromide [usan]

9. Tazverik

10. Ez-438

11. 6p89t5m073

12. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:1)

13. N-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide

14. Unii-6p89t5m073

15. Tazverik (tn)

16. 1467052-77-2

17. Chembl4594260

18. Schembl15313373

19. Dtxsid101027715

20. Hy-13803c

21. Tazemetostat Hydrobromide (jan/usan)

22. Tazemetostat Hydrobromide [jan]

23. Tazemetostat Hydrobromide [who-dd]

24. Epz-6438 Hydrobromide; Tazemetostat Hbr

25. Cs-0101826

26. D11485

27. Tazemetostat Hydrobromide [orange Book]

28. Q27265267

29. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide

30. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide Hydrobromide

31. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamidehydrobromide

2.4 Create Date
2013-11-04
3 Chemical and Physical Properties
Molecular Weight 653.6 g/mol
Molecular Formula C34H45BrN4O4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count9
Exact Mass652.26242 g/mol
Monoisotopic Mass652.26242 g/mol
Topological Polar Surface Area83.1 Ų
Heavy Atom Count43
Formal Charge0
Complexity992
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2

NDC API

read-more
read-more

01

Medlab Asia & Asia Health
Not Confirmed
arrow
arrow
Medlab Asia & Asia Health
Not Confirmed

TAZEMETOSTAT HYDROBROMIDE

NDC Package Code : 50384-4000

Start Marketing Date : 2020-01-23

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (160kg/160kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1627583400,"product":"TAZEMETOSTAT(TAX INV NO:1905215151 DT:30 7.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"SANDOZ B2B","customerCountry":"SLOVENIA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"25372.7","totalValueFC":"49058.9","currency":"USD","unitRateINR":1828099.5,"date":"30-Jul-2021","totalValueINR":"3656199","totalValueInUsd":"49058.9","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"3513012","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727634600,"product":"TAZEMETOSTAT HYDROBROMIDE(ESQR) (100027123)","address":"PLOT NO.135, DR.NO.10-153\/1,","city":"VISAKHAPATNAM, ANDHRA PRADESH","supplier":"EISAI","supplierCountry":"INDIA","foreign_port":"NARITA APT\/TOKYO, 12","customer":"EISAI","customerCountry":"JAPAN","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"2328833.3","totalValueFC":"639752.7","currency":"JPY","unitRateINR":1340301.53525,"date":"30-Sep-2024","totalValueINR":"53612061.41","totalValueInUsd":"639752.7","indian_port":"Vizag-RPCIPL SEZ","hs_no":"29420090","bill_no":"4449218","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-RPCIPL SEZ","supplierAddress":"PLOT NO.135, DR.NO.10-153\/1,, VISAKHAPATNAM, ANDHRA PRADESH","customerAddress":""}]
30-Jul-2021
30-Sep-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

INTERMEDIATES SUPPLIERS

read-more
read-more

01

Minakem

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMinakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

CAS Number : 29943-42-8

End Use API : Tazemetostat

About The Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&...

Minakem Comapny Banner

02

Pharmtech & Ingredients
Not Confirmed
arrow
Pharmtech & Ingredients
Not Confirmed
arrow

CAS Number : 107650-20-4

End Use API : Tazemetostat

About The Company : Saflik Pharma is a registered company that was started with the aim of providing top notch quality of pharmaceutical API’s and Intermediates to our buyers. We...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty